Your browser doesn't support javascript.
loading
Ganglionic Acetylcholine Receptor Antibodies in Postural Tachycardia Syndrome.
Bryarly, Meredith; Raj, Satish R; Phillips, Lauren; Hynan, Linda S; Okamoto, Luis E; Arnold, Amy C; Paranjape, Sachin Y; Vernino, Megan; Black, Bonnie K; Vernino, Steven.
Afiliação
  • Bryarly M; Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvan
  • Raj SR; Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvan
  • Phillips L; Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvan
  • Hynan LS; Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvan
  • Okamoto LE; Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvan
  • Arnold AC; Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvan
  • Paranjape SY; Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvan
  • Vernino M; Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvan
  • Black BK; Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvan
  • Vernino S; Department of Neurology (MB, LP, MV, SV), UT Southwestern Medical Center, Dallas; Autonomic Dysfunction Center (SRR, LEO, ACA, SYP, BKB), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Neural & Behavioral Sciences (ACA), Pennsylvan
Neurol Clin Pract ; 11(4): e397-e401, 2021 Aug.
Article em En | MEDLINE | ID: mdl-34484936
ABSTRACT

OBJECTIVE:

Postural tachycardia syndrome (POTS), the most common form of dysautonomia, may be associated with autoimmunity in some cases. Autoantibodies against the ganglionic acetylcholine receptor (gAChR) have been reported in a minority of patients with POTS, but the prevalence and clinical relevance is unclear.

METHODS:

Clinical information and serum samples were systematically collected from participants with POTS and healthy control volunteers (n = 294). The level of positive gAChR antibodies was classified as very low (0.02-0.05 nmol/L), low (0.05-0.2 nmol/L), and high (>0.2 nmol/L).

RESULTS:

Fifteen of 217 patients with POTS (7%) had gAChR antibodies (8 very low and 7 low). Six of the 77 healthy controls (8%) were positive (3 very low and 3 low). There were no clinical differences between seropositive and seronegative patients with POTS.

CONCLUSIONS:

Prevalence of gAChR antibody did not differ between POTS and healthy controls, and none had high antibody levels. Patients with POTS were not clinically different based on seropositivity. Low levels of gAChR antibodies are not clinically important in POTS.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Neurol Clin Pract Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Neurol Clin Pract Ano de publicação: 2021 Tipo de documento: Article